Cumberland Pharmaceuticals (CPIX) Net Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -517.34% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | -88.52% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 3,465.10% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 270.63% |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | -1,243.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,243.98% |
| Mar 31, 2026 | 84.68% |
| Dec 31, 2025 | -851.27% |
| Sep 30, 2025 | -794.06% |
| Jun 30, 2025 | 180.76% |
| Mar 31, 2025 | -1,358.82% |
| Dec 31, 2024 | 368.02% |
| Sep 30, 2024 | -50.44% |
| Jun 30, 2024 | -165.06% |
| Mar 31, 2024 | 106.73% |
| Dec 31, 2023 | -186.10% |
| Sep 30, 2023 | -80.46% |
| Jun 30, 2023 | 96.14% |
| Mar 31, 2023 | 65.50% |
| Dec 31, 2022 | -81.93% |
| Sep 30, 2022 | 666.90% |
| Jun 30, 2022 | 27.05% |
| Mar 31, 2022 | -5,879.04% |
| Dec 31, 2021 | 163.27% |
| Sep 30, 2021 | 123.76% |